Free

Cardiomyocytes for Mechanistic CV Safety Liabilities

Event Information

Share this event

Date and Time

Location

Location

FDA White Oak Bldg 31

10903 New Hampshire Avenue

Building 31 Conference Center, the Great Room

White Oak, MD 20993

View Map

Event description

Description

Date: March 29, 2019

Time: 8:30 am to 4:30 pm

Location: FDA White Oak Campus
Building 31, Room 1503 – Great Room
10903 New Hampshire Avenue
Silver Spring, MD 20993
FDA Campus Information, (e.g., local airports, directions, and local hotels)

Registration:

Persons interested in attending this public workshop must register online at https://www.eventbrite.com/e/cardiomyocytes-for-mechanistic-cv-safety-liabilities-tickets-54353537895 by 5 p.m. on March 27, 2019.

Background:

Cardiovascular safety liabilities remain an important concern in drug development that impacts candidate attrition and may lead to adverse clinical events. These liabilities (as evidenced by various oncology drugs) span the spectrum of arrhythmias, contractile dysfunction, myocardial injury and inflammation, blood pressure control and even valvular dysfunction.

Recently, a variety of quantitative functional, biochemical and imaging biomarkers measured with human pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in medium to higher throughput assays have been studied. These assays have the potential of reducing drug-induced cardiotoxicity with novel therapeutics (and promising combination pharmacological therapies) early in drug discovery while reducing reliance on traditional (and often nonspecific) animal toxicity studies.

This session will focus on the use of hiPSC-CMs in nonclinical studies to guide early drug discovery efforts in human-relevant models and provide mechanistic insights into cardiac contractile and structural liabilities and recognized failure modes. We will discuss strengths and limitations of current capabilities, describe technical requirements for such a paradigm, cite study examples, and discuss strategies for validating, qualifying and building confidence in the relevance of this approach. Regulatory nonclinical reviewers, experts in the use of hiPSC-CMs, drug developers, and academics will share perspectives on the value of this evolving paradigm, and identify paths forward for appropriate “fit for purpose” applications to be used by industry and regulators to ensure drug safety for patients.

Workshop Information: (documents will be added when available to meeting webpage)

Meeting Webpage

  • DRAFT Agenda
  • List of Speakers and Panelists
  • Planning Committee
Share with friends

Date and Time

Location

FDA White Oak Bldg 31

10903 New Hampshire Avenue

Building 31 Conference Center, the Great Room

White Oak, MD 20993

View Map

Save This Event

Event Saved